The abstract is read at the publisher; the summary is JClub's.
Depressive syndromes in Alzheimer’s disease (AD) and Parkinson’s disease (PD) affect more than one-third of patients and are linked to accelerated cognitive decline and higher healthcare use.
- Why it matters: Standard antidepressants show little or no efficacy in these neurodegenerative populations, and cognitive impairment is often excluded from trials, leaving mechanisms and treatments under-tested.
- What they did: This narrative review synthesizes evidence from molecular imaging, neuropathology, and cognitive neuroscience, and evaluates emerging pharmacological and neuromodulatory approaches targeting glutamatergic, serotonergic, dopaminergic, immune, and reward-related circuit dysfunction.
- The result: Disease-specific monoaminergic, glutamatergic, inflammatory, and reward-circuit disruptions may undermine standard antidepressant mechanisms, supporting mechanistically guided development of glutamate modulators, dopaminergic agents, kappa opioid antagonists, immune therapies, and next-generation brain stimulation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.